Group waits for ANVISA’s decision to invest in medicinal cannabis
January 4, 2019
Piauhy Labs announces its latest funding round led by Migration Capital
May 4, 2021Piauhy Labs Portugal receives approval from the Portuguese regulatory agency for its medicinal cannabis project
Lisbon, Portugal, September 16th.
According to Eduardo Sampaio, CEO and founder of the company: “We are very happy
with this important milestone and the ratification of our project, a project based on three
pillars: scientific dedication, focus on the patient and adherence to the best practices in the
pharmaceutical industry”. According to Sampaio: “We believe in science. We have a solid
scientific conviction that medicinal products derived from these plants effectively help the
treatment of a large number of diseases. It is a belief supported by a large, relevant, and
growing number of scientific studies that justify the use of phytocannabic products for an
equally growing number of diseases. We are very clear about our objective: bring
phytocannabic products to patients, produced within the highest quality standards and at
affordable prices. We have as a commitment and starting point to execute all stages of
development of this project in full compliance with the regulatory frameworks and the
legislation in force ”.
Eduardo Sampaio has accumulated several years of success and experience in this
segment. About five years ago, he started the first medical cannabis company in Uruguay
with other partners and he subsequently developed an online marketplace for hemp food
products in Australia.
According to Sampaio, the success of Piauhy Labs is intrinsically linked to the scientific
research he intends to start later this year in Portugal in partnership with local universities
and scientific partners in Brazil and California.
“We are building a pharmaceutical
company. This is not an agricultural project, but a real pharmaceutical company - and this
is only possible with attention and dedication to research and development ”says
Sampaio. "This is one of the main differentials of the Piauhy Labs project in relation to other
companies".
“We already have a pipeline of experiments and product development that we will start in
the coming weeks. We chose three diseases for our first research: epilepsy, autism
spectrum disorder (ASD) and Alzheimer's. The first two lead applications for the use of
medical cannabis in several countries such as Brazil, while the third is the one with the
greatest potential for innovation”.
In parallel to its research, Piauhy Labs will start the construction of its high-end factory
capable of micropropagation of mother plants, indoor cultivation with LED lamps, and
extraction with supercritical carbon dioxide. According to Sampaio, these choices are
justified: “All the techniques that we are going to use in our factory represent the cutting
edge processes of the medical cannabis industry. With that, we will achieve a
differentiated product with more quality and scientific rigor”.
Piauhy Labs Portugal receives approval from the Portuguese regulatory agency for its medicinal cannabis project
Lisbon, Portugal, September 16th.
According to Eduardo Sampaio, CEO and founder of the company: “We are very happy
with this important milestone and the ratification of our project, a project based on three
pillars: scientific dedication, focus on the patient and adherence to the best practices in the
pharmaceutical industry”. According to Sampaio: “We believe in science. We have a solid
scientific conviction that medicinal products derived from these plants effectively help the
treatment of a large number of diseases. It is a belief supported by a large, relevant, and
growing number of scientific studies that justify the use of phytocannabic products for an
equally growing number of diseases. We are very clear about our objective: bring
phytocannabic products to patients, produced within the highest quality standards and at
affordable prices. We have as a commitment and starting point to execute all stages of
development of this project in full compliance with the regulatory frameworks and the
legislation in force ”.
Eduardo Sampaio has accumulated several years of success and experience in this
segment. About five years ago, he started the first medical cannabis company in Uruguay
with other partners and he subsequently developed an online marketplace for hemp food
products in Australia.
According to Sampaio, the success of Piauhy Labs is intrinsically linked to the scientific
research he intends to start later this year in Portugal in partnership with local universities
and scientific partners in Brazil and California.
“We are building a pharmaceutical
company. This is not an agricultural project, but a real pharmaceutical company - and this
is only possible with attention and dedication to research and development ”says
Sampaio. "This is one of the main differentials of the Piauhy Labs project in relation to other
companies".
“We already have a pipeline of experiments and product development that we will start in
the coming weeks. We chose three diseases for our first research: epilepsy, autism
spectrum disorder (ASD) and Alzheimer's. The first two lead applications for the use of
medical cannabis in several countries such as Brazil, while the third is the one with the
greatest potential for innovation”.
In parallel to its research, Piauhy Labs will start the construction of its high-end factory
capable of micropropagation of mother plants, indoor cultivation with LED lamps, and
extraction with supercritical carbon dioxide. According to Sampaio, these choices are
justified: “All the techniques that we are going to use in our factory represent the cutting
edge processes of the medical cannabis industry. With that, we will achieve a
differentiated product with more quality and scientific rigor”.
